Emerging Insights into Malaria

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Microbiology in Human Health and Disease".

Deadline for manuscript submissions: closed (29 February 2024) | Viewed by 1255

Special Issue Editors


E-Mail Website
Guest Editor
Instituto Leônidas & Maria Deane, ILMD/FIOCRUZ Amazonia, Manaus, Brazil
Interests: malaria pathogenesis; antimalarial treatment; plasmodium-vector interaction

E-Mail Website
Co-Guest Editor
Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil
Interests: malarial treatment; diagnostic; resistance to antimalarial; malaria pathogenesis

Special Issue Information

Dear Colleagues,

Despite the efforts and measures implemented over many years to control malaria, it is still one of the most prevalent public health concerns in the world. Several studies have been performed in recent decades to elucidate the mechanisms involved in its pathogenesis and host–parasite relationship, the discovery of novel drugs for treatment and chemoprevention, and the application of vaccines and methodology employed for vector control, among others. The results of this and future research may elucidate mechanisms that support the goals of malaria control and elimination. This Special Issue will address all research that provides new insights into the pathogenesis, novel treatments or treatment regimens, diagnostic methodologies, and control of malaria vector mosquitoes.

Dr. Djane Baia-da-Silva
Dr. Gisely Cardoso De Melo
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • malaria pathogenesis
  • malaria treatment
  • malaria diagnosis
  • malaria control
  • malaria vector

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 3184 KiB  
Article
Are pvcrt-o and pvmdr1 Gene Mutations Associated with Plasmodium vivax Chloroquine-Resistant Parasites?
by Rebecca de Abreu-Fernandes, Natália Ketrin Almeida-de-Oliveira, Aline Rosa de Lavigne Mello, Lucas Tavares de Queiroz, Jacqueline de Aguiar Barros, Bárbara de Oliveira Baptista, Joseli Oliveira-Ferreira, Rodrigo Medeiros de Souza, Lilian Rose Pratt-Riccio, Patrícia Brasil, Cláudio Tadeu Daniel-Ribeiro and Maria de Fátima Ferreira-da-Cruz
Biomedicines 2024, 12(1), 141; https://doi.org/10.3390/biomedicines12010141 - 9 Jan 2024
Cited by 1 | Viewed by 987
Abstract
(1) Background: Malaria remains a significant global public health issue. Since parasites quickly became resistant to most of the available antimalarial drugs, treatment effectiveness must be constantly monitored. In Brazil, up to 10% of cases of vivax malaria resistant to chloroquine (CQ) have [...] Read more.
(1) Background: Malaria remains a significant global public health issue. Since parasites quickly became resistant to most of the available antimalarial drugs, treatment effectiveness must be constantly monitored. In Brazil, up to 10% of cases of vivax malaria resistant to chloroquine (CQ) have been registered. Unlike P. falciparum, there are no definitive molecular markers for the chemoresistance of P. vivax to CQ. This work aimed to investigate whether polymorphisms in the pvcrt-o and pvmdr1 genes could be used as markers for assessing its resistance to CQ. (2) Methods: A total of 130 samples from P. vivax malaria cases with no clinical and/or parasitological evidence of CQ resistance were studied through polymerase chain reaction for gene amplification followed by target DNA sequencing. (3) Results: In the pvcrt-o exons, the K10 insert was present in 14% of the isolates. Regarding pvmdr1, T958M and F1076L haplotypes showed frequencies of 95% and 3%, respectively, while the SNP Y976F was not detected. (4) Conclusions: Since K10-pvcrt-o and F1076L/T958M-pvmdr1 polymorphisms were detected in samples from patients who responded well to CQ treatment, it can be concluded that mutations in these genes do not seem to have a potential for association with the phenotype of CQ resistance. Full article
(This article belongs to the Special Issue Emerging Insights into Malaria)
Show Figures

Figure 1

Back to TopTop